Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 199

1.

What do functional genomics tell us about pathogenesis of AML?

Tyner JW, Bottomly D, Wilmot B, McWeeney S.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101101. doi: 10.1016/j.beha.2019.101101. Epub 2019 Oct 18. Review.

PMID:
31779979
2.

Replication timing alterations in leukemia affect clinically relevant chromosome domains.

Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, Eaves CJ, Gilbert DM.

Blood Adv. 2019 Nov 12;3(21):3201-3213. doi: 10.1182/bloodadvances.2019000641.

3.

Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.

Choonoo G, Blucher AS, Higgins S, Boardman M, Jeng S, Zheng C, Jacobs J, Anderson A, Chamberlin S, Evans N, Vigoda M, Cordier B, Tyner JW, Kulesz-Martin M, McWeeney SK, Laderas T.

PLoS One. 2019 Oct 9;14(10):e0223639. doi: 10.1371/journal.pone.0223639. eCollection 2019.

4.

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.

Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.

5.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
6.

SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells.

Sun QY, Ding LW, Johnson K, Zhou S, Tyner JW, Yang H, Doan NB, Said JW, Xiao JF, Loh XY, Ran XB, Venkatachalam N, Lao Z, Chen Y, Xu L, Fan LF, Chien W, Lin DC, Koeffler HP.

Oncogene. 2019 Aug;38(34):6196-6210. doi: 10.1038/s41388-019-0865-8. Epub 2019 Jul 22.

PMID:
31332289
7.

Bilateral brachiocephalic vein and superior vena cava reconstruction with an aortic allograft.

Tyner J, Baradarian S, Armstrong B, Cutter S.

Ann Thorac Surg. 2019 Jun 21. pii: S0003-4975(19)30868-9. doi: 10.1016/j.athoracsur.2019.04.102. [Epub ahead of print]

PMID:
31233724
8.

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.

Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.

PMID:
31048320
9.

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Mar 29;8. pii: e47174. doi: 10.7554/eLife.47174.

10.

Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity.

Rozanov D, Cheltsov A, Nilsen A, Boniface C, Forquer I, Korkola J, Gray J, Tyner J, Tognon CE, Mills GB, Spellman P.

PLoS One. 2019 Mar 25;14(3):e0205623. doi: 10.1371/journal.pone.0205623. eCollection 2019.

11.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.

Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators.

N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16.

PMID:
30883053
12.

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Feb 5;8. pii: e40033. doi: 10.7554/eLife.40033. Erratum in: Elife. 2019 Mar 29;8:.

13.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

14.

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.

Leuk Res. 2019 Feb;77:42-50. doi: 10.1016/j.leukres.2018.11.010. Epub 2019 Jan 7.

15.

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.

Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP.

Haematologica. 2019 Jun;104(6):1209-1220. doi: 10.3324/haematol.2018.201483. Epub 2019 Jan 3.

16.

Two myeloid leukemia cases with rare FLT3 fusions.

Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW.

Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003079. doi: 10.1101/mcs.a003079. Print 2018 Dec.

17.

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Edwards DK 5th, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, McWeeney SK, Tyner JW.

Blood. 2019 Feb 7;133(6):588-599. doi: 10.1182/blood-2018-03-838946. Epub 2018 Nov 13.

PMID:
30425048
18.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

19.

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.

Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC.

Oncogene. 2019 Feb;38(8):1200-1210. doi: 10.1038/s41388-018-0508-5. Epub 2018 Sep 21.

20.

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.

Leukemia. 2018 Sep;32(9):2025-2028. doi: 10.1038/s41375-018-0225-7. Epub 2018 Aug 6. No abstract available.

Supplemental Content

Loading ...
Support Center